NCT01782976 2018-01-19
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT01517776 2015-07-21
HGG-CilMetro
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Terminated
NCT01044225 2012-03-22
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
Universitair Ziekenhuis Brussel
Phase 2 Terminated
NCT01124240 2011-07-26
ExCentric
Northern Sydney and Central Coast Area Health Service
Phase 2 Unknown